Estrogen Receptor-alpha 36 Mediates the Anti-apoptotic Effect of Estradiol in Triple Negative Breast Cancer Cells Via a Membrane-associated Mechanism
Overview
Biophysics
Affiliations
17β-Estradiol can promote the growth and development of several estrogen receptor (ER)-negative breast cancers. The effects are rapid and non-genomic, suggesting that a membrane-associated ER is involved. ERα36 has been shown to mediate rapid, non-genomic, membrane-associated effects of 17β-estradiol in several cancer cell lines, including triple negative HCC38 breast cancer cells. Moreover, the effect is anti-apoptotic. The aim of this study was to determine if ERα36 mediates this anti-apoptotic effect, and to elucidate the mechanism involved. Taxol was used to induce apoptosis in HCC38 cells, and the effect of 17β-estradiol pre-treatment was determined. Antibodies to ERα36, signal pathway inhibitors, ERα36 deletion mutants, and ERα36-silencing were used prior to these treatments to determine the role of ERα36 in these effects and to determine which signaling molecules were involved. We found that the anti-apoptotic effect of 17β-estradiol in HCC38 breast cancer cells is in fact mediated by membrane-associated ERα36. We also showed that this signaling occurs through a pathway that requires PLD, LPA, and PI3K; Gαs and calcium signaling may also be involved. In addition, dynamic palmitoylation is required for the membrane-associated effect of 17β-estradiol. Exon 9 of ERα36, a unique exon to ERα36 not found in other identified splice variants of ERα with previously unknown function, is necessary for these effects. This study provides a working model for a mechanism by which estradiol promotes anti-apoptosis through membrane-associated ERα36, suggesting that ERα36 may be a potential membrane target for drug design against breast cancer, particularly triple negative breast cancer.
Falsetti I, Palmini G, Zonefrati R, Vasa K, Donati S, Aurilia C Int J Mol Sci. 2025; 26(5).
PMID: 40076925 PMC: 11900421. DOI: 10.3390/ijms26052305.
Cohen D, Dennis C, Deng J, Boyan B, Schwartz Z JBMR Plus. 2024; 8(5):ziae041.
PMID: 38644978 PMC: 11032217. DOI: 10.1093/jbmrpl/ziae041.
ER-α36 is involved in calycosin inhibition of IL-6 production in macrophages.
Wu G, Qi G, Liu Y, Gan J, Xie C, Wu Q J Cell Mol Med. 2023; 28(1):e18037.
PMID: 37974543 PMC: 10805506. DOI: 10.1111/jcmm.18037.
14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
Garan L, Xiao Y, Lin W Proc Natl Acad Sci U S A. 2022; 119(43):e2209211119.
PMID: 36252018 PMC: 9618134. DOI: 10.1073/pnas.2209211119.
Shanta K, Nakayama K, Hossain M, Razia S, Ishibashi T, Ishikawa M Curr Oncol. 2022; 29(6):4020-4033.
PMID: 35735430 PMC: 9221871. DOI: 10.3390/curroncol29060321.